Computational Approaches to Toll-Like Receptor 4 Modulation

Molecules

Volumn 21, Issue 8, 2016, Pages

  Billod, Jean Marc ^a   Lacetera, Alessandra ^a   Guzmán Caldentey, Joan ^a   Martín Santamaría, Sonsoles ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Computational chemistry; Docking; Drug design; Homology modeling; Md simulations; Molecular recognition; Tlr4 md 2 modulators; Toll like receptor 4; Virtual screening

Indexed keywords

LIPOPOLYSACCHARIDE; LY96 PROTEIN, HUMAN; MOLECULAR LIBRARY; PROTEIN MD 2; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

BIOLOGY; CHEMISTRY; DRUG DESIGN; GRAM NEGATIVE BACTERIUM; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MODEL; PHARMACOLOGY; PROCEDURES; STRUCTURAL HOMOLOGY; X RAY CRYSTALLOGRAPHY;

COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; GRAM-NEGATIVE BACTERIA; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES; STRUCTURAL HOMOLOGY, PROTEIN; TOLL-LIKE RECEPTOR 4;

EID: 84982732343     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21080994     Document Type: Review

References (87)

1. Beutler, B. TLR4 as the mammalian endotoxin sensor. Curr. Top. Microbiol. Immunol. 2002, 270, 109-120.
2. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4, 499-511.
3. Klett, J.; Reeves, J.; Oberhauser, N.; Perez-Regidor, L.; Martin-Santamaria, S. Modulation of Toll-like receptor 4. Insights from X-ray crystallography and molecular modeling. Curr. Top. Med. Chem. 2014, 14, 2672-2683.
4. Schletter, J.;Heine, H.; Ulmer, A.J.; Rietschel, E.T. Molecular mechanisms of endotoxin activity. Arch. Microbiol. 1995, 164, 383-389.
5. Meng, J.; Lien, E.; Golenbock, D.T. MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation. J. Biol. Chem. 2010, 285, 8695-8702.
6. Molinaro, A.; Holst, O.; di Lorenzo, F.; Callaghan, M.; Nurisso, A.; D'Errico, G.; Zamyatina, A.; Peri, F.; Berisio, R.; Jerala, R.; et al. Chemistry of lipid A: At the heart of innate immunity. Chem. Eur. J. 2015, 21, 500-519.
7. Di Lorenzo, F.; Kubik,Ł.; Oblak, A.; Lorè, N.I.; Cigana, C.; Lanzetta, R.; Parrilli, M.; Hamad, M.A.; de Soyza, A.; Silipo, A. Activation of human Toll-like receptor 4 (TLR4)· myeloid differentiation factor 2 (MD-2) by hypoacylated lipopolysaccharide from a clinical isolate of burkholderia cenocepacia. J. Biol. Chem. 2015, 290, 21305-21319.
8. Maeshima, N.; Evans-Atkinson, T.; Hajjar, A.M.; Fernandez, R.C. Bordetella pertussis lipid A recognition by Toll-like receptor 4 and MD-2 is dependent on distinct charged and uncharged interfaces. J. Biol. Chem. 2015, 290, 13440-13453.
9. Ohto, U.; Fukase, K.; Miyake, K.; Shimizu, T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc. Natl. Acad. Sci. USA 2012, 109, 7421-7426.
10. Resman, N.; Vašl, J.; Oblak, A.; Pristovšek, P.; Gioannini, T.L.; Weiss, J.P.; Jerala, R. Essential roles of hydrophobic residues in both MD-2 and Toll-like receptor 4 in activation by endotoxin. J. Biol. Chem. 2009, 284, 15052-15060.
11. Ohto, U.; Fukase, K.; Miyake, K.; Satow, Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007, 316, 1632-1634.
12. Scior, T.; Alexander, C.; Zaehringer, U. Reviewing and identifying amino acids of human, murine, canine and equine TLR4/MD-2 receptor complexes conferring endotoxic innate immunity activation by LPS/lipid A, or antagonistic effects by eritoran, in contrast to species-dependent modulation by lipid IVa. Comput. Struct. Biotechnol. J. 2013, 5, 1-13.
13. Kim, H.M.; Park, B.S.; Kim, J.-I.; Kim, S.E.; Lee, J.; Oh, S.C.; Enkhbayar, P.; Matsushima, N.; Lee, H.; Yoo, O.J. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007, 130, 906-917.
14. Scior, T.; Lozano-Aponte, J.; Figueroa-Vazquez, V.; Yunes-Rojas, J.A.; Zähringer, U.; Alexander, C. Three-dimensional mapping of differential amino acids of human, murine, canine and equine TLR4/MD-2 receptor complexes conferring endotoxic activation by lipid A, antagonism by eritoran and species-dependent activities of lipid IVa in the mammalian lps sensor system. Comput. Struct. Biotechnol. J. 2013, 7, 1-11.
15. Peri, F.; Calabrese, V. Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: An update. J. Med. Chem. 2014, 57, 3612-3622.
16. Hennessy, E.J.; Parker, A.E.; O'Neill, L.A. Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 2010, 9, 293-307.
17. Garate, J.A.; Oostenbrink, C. Lipid A from lipopolysaccharide recognition: Structure, dynamics and cooperativity by molecular dynamics simulations. Proteins Struct. Funct. Bioinf. 2013, 81, 658-674.
18. DeMarco, M.L.; Woods, R.J. From agonist to antagonist: Structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins. Mol. Immunol. 2011, 49, 124-133.
19. Paramo, T.; Piggot, T.J.; Bryant, C.E.; Bond, P.J. The structural basis for endotoxin-induced allosteric regulation of the Toll-like receptor 4 (TLR4) innate immune receptor. J. Biol. Chem. 2013, 288, 36215-36225.
20. Yu, L.; Phillips, R.L.; Zhang, D.; Teghanemt, A.; Weiss, J.P.; Gioannini, T.L. NMR studies of hexaacylated endotoxin bound to wild-type and F126A mutant MD-2 and MD-2 TLR4 ectodomain complexes. J. Biol. Chem. 2012, 287, 16346-16355.
21. De Aguiar, C.; Costa, M.G.; Verli, H. Dynamics on human Toll-like receptor 4 complexation to MD-2: The coreceptor stabilizing function. Proteins Struct. Funct. Bioinf. 2015, 83, 373-382.
22. Anwar, M.A.; Panneerselvam, S.; Shah, M.; Choi, S. Insights into the species-specific TLR4 signaling mechanism in response to Rhodobacter sphaeroides lipid A detection. Sci. Rep. 2015, 5, 7657.
23. Slivka, P.F.; Shridhar, M.; Lee, G.i.; Sammond, D.W.; Hutchinson, M.R.; Martinko, A.J.; Buchanan, M.M.; Sholar, P.W.; Kearney, J.J.; Harrison, J.A. A peptide antagonist of the TLR4-MD2 interaction. ChemBioChem 2009, 10, 645-649.
24. Rohl, C.A.; Strauss, C.E.; Misura, K.M.; Baker, D. Protein structure prediction using rosetta. Methods Enzymol. 2004, 383, 66-93.
25. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock 4 and AuutoDockTools 4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785-2791.
26. Trott, O.; Olson, A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455-461.
27. Klett, J.; Nunez-Salgado, A.; Dos Santos, H.G.; Cortes-Cabrera, A.; Perona, A.; Gil-Redondo, R.; Abia, D.; Gago, F.; Morreale, A. Mm-ismsa: An ultrafast and accurate scoring function for protein-protein docking. J. Chem. Theory Comput. 2012, 8, 3395-3408.
28. Vašl, J.; Oblak, A.; Peternelj, T.T.; Klett, J.; Martín-Santamaría, S.; Gioannini, T.L.; Weiss, J.P.; Jerala, R. Molecular basis of the functional differences between soluble human versus murine MD-2: Role of Val135 in transfer of lipopolysaccharide from CD14 to MD-2. J. Immunol. 2016, 196, 2309-2318.
29. Barochia, A.; Solomon, S.; Cui, X.; Natanson, C.; Eichacker, P.Q. Eritoran tetrasodium (e5564) treatment for sepsis: Review of preclinical and clinical studies. Expert Opin. Drug Metab. Toxicol. 2011, 7, 479-494.
30. Krivov, G.G.; Shapovalov, M.V.; Dunbrack, R.L., Jr. Improved prediction of protein side-chain conformations with SCWRL4. Proteins 2009, 77, 778-795.
31. Cighetti, R.; Ciaramelli, C.; Sestito, S.E.; Zanoni, I.; Kubik,Ł; Ardá-Freire, A.; Calabrese, V.; Granucci, F.; Jerala, R.; Martín-Santamaría, S. Modulation of CD14 and TLR4?MD-2 activities by a synthetic lipid A mimetic. ChemBioChem 2014, 15, 250-258.
32. Glide & Impact software. Available online: http://www.schrodinger.com (accessed on 26 July 2016).
33. Garate, J.A.; Stöckl, J.; Fernández-Alonso, M.D.C.; Artner, D.; Haegman, M.; Oostenbrink, C.; Jiménez-Barbero, J.; Beyaert, R.; Heine, H.; Kosma, P. Anti-endotoxic activity and structural basis for human MD-2?TLR4 antagonism of tetraacylated lipid A mimetics based on βglcn (1∅1) αglcn scaffold. Innate Immun. 2015, 21, 490-503.
34. Piazza, M.; Calabrese, V.; Baruffa, C.; Gioannini, T.; Weiss, J.; Peri, F. The cationic amphiphile 3,4-bis(tetradecyloxy)benzylamine inhibits LPS signaling by competing with endotoxin for CD14 binding. Biochem. Pharmacol. 2010, 80, 2050-2056.
35. Ciaramelli, C.; Calabrese, V.; Sestito, S.E.; Pérez-Regidor, L.; Klett, J.; Oblak, A.; Jerala, R.; Piazza, M.; Martín-Santamaría, S.; Peri, F. Glycolipid-based TLR4 modulators and fluorescent probes: Rational design, synthesis, and biological properties. Chem. Biol. Drug Des. 2016.
36. Dundas, J.; Ouyang, Z.; Tseng, J.; Binkowski, A.; Turpaz, Y.; Liang, J. Castp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006, 34, W116-W118.
37. Webb, B.; Sali, A. Comparative protein structure modeling using modeller. Curr. Protoc. Bioinform. 2014, 47.
38. Walsh, C.; Gangloff, M.; Monie, T.; Smyth, T.; Wei, B.; McKinley, T.J.; Maskell, D.; Gay, N.; Bryant, C. Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVa. J. Immunol. 2008, 181, 1245-1254.
39. Irvine, K.L.; Gangloff, M.; Walsh, C.M.; Spring, D.R.; Gay, N.J.; Bryant, C.E. Identification of key residues that confer rhodobacter sphaeroides LPS activity at horse TLR4/MD-2. PLoS ONE 2014, 9, e98776.
40. Kawasaki, K.; Akashi, S.; Shimazu, R.; Yoshida, T.; Miyake, K.; Nishijima, M. Mouse Toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol. J. Biol. Chem. 2000, 275, 2251-2254.
41. Manthey, C.L.; Qureshi, N.; Stutz, P.L.; Vogel, S.N. Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J. Exp. Med. 1993, 178, 695-702.
42. Resman, N.; Gradišar, H.; Vašl, J.; Keber, M.M.; Pristovšek, P.; Jerala, R. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS Lett. 2008, 582, 3929-3934.
43. Zimmer, S.M.; Liu, J.; Clayton, J.L.; Stephens, D.S.; Snyder, J.P. Paclitaxel binding to human and murine MD-2. J. Biol. Chem. 2008, 283, 27916-27926.
44. Sybyl-x Suite. Available online: https://www.certara.com/software/molecular-modeling-and-simulation/ sybyl-x-suite/ (accessed on 26 July 2016).
45. Fu, W.; Chen, L.; Wang, Z.; Zhao, C.; Chen, G.; Liu, X.; Dai, Y.; Cai, Y.; Li, C.; Zhou, J. Determination of the binding mode for anti-inflammatory natural product xanthohumol with myeloid differentiation protein 2. Drug Des. Dev. Ther. 2016, 10, 455-463.
46. Wang, Z.; Chen, G.; Chen, L.; Liu, X.; Fu, W.; Zhang, Y.; Li, C.; Liang, G.; Cai, Y. Insights into the binding mode of curcumin to MD-2: Studies from molecular docking, molecular dynamics simulations and experimental assessments. Mol. Biosyst. 2015, 11, 1933-1938.
47. Chan, M.; Hayashi, T.; Mathewson, R.D.; Nour, A.; Hayashi, Y.; Yao, S.; Tawatao, R.I.; Crain, B.; Tsigelny, I.F.; Kouznetsova, V.L.; et al. Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J. Med. Chem. 2013, 56, 4206-4223.
48. Nour, A.; Hayashi, T.; Chan, M.; Yao, S.; Tawatao, R.I.; Crain, B.; Tsigelny, I.F.; Kouznetsova, V.L.; Ahmadiiveli, A.; Messer, K. Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands. Bioorg. Med. Chem. Lett. 2014, 24, 4931-4938.
49. Koo, J.E.; Park, Z.-Y.; Kim, N.D.; Lee, J.Y. Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2. Biochem. Biophys. Res. Commun. 2013, 434, 600-605.
50. Kim, S.Y.; Koo, J.E.; Seo, Y.J.; Tyagi, N.; Jeong, E.; Choi, J.; Lim, K.M.; Park, Z.Y.; Lee, J.Y. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Br. J. Pharmacol. 2013, 168, 1933-1945.
51. Bevan, D.E.; Martinko, A.J.; Loram, L.C.; Stahl, J.A.; Taylor, F.R.; Joshee, S.; Watkins, L.R.; Yin, H. Selection, preparation, and evaluation of small-molecule inhibitors of Toll-like receptor 4. ACS Med. Chem. Lett. 2010, 1, 194-198.
52. Byun, E.B.; Sung, N.Y.; Byun, E.H.; Song, D.S.; Kim, J.K.; Park, J.H.; Song, B.S.; Park, S.H.; Lee, J.W.; Byun, M.W.; et al. The procyanidin trimer C1 inhibits LPS-induced MAPK and NF-κB signaling through TLR4 in macrophages. Int. Immunopharmacol. 2013, 15, 450-456.
53. Terra, X.; Palozza, P.; Fernandez-Larrea, J.; Ardevol, A.; Blade, C.; Pujadas, G.; Salvado, J.; Arola, L.; Blay, M.T. Procyanidin dimer B1 and trimer C1 impair inflammatory response signalling in human monocytes. Free Radic. Res. 2011, 45, 611-619.
54. Jung, M.; Triebel, S.; Anke, T.; Richling, E.; Erkel, G. Influence of apple polyphenols on inflammatory gene expression. Mol. Nutr. Food Res. 2009, 53, 1263-1280.
55. Xing, J.; Li, R.; Li, N.; Zhang, J.; Li, Y.; Gong, P.; Gao, D.; Liu, H.; Zhang, Y. Anti-inflammatory effect of procyanidin B1 on LPS-treated THP1 cells via interaction with the TLR4-MD-2 heterodimer and p38 MAPK and NF-κB signaling. Mol. Cell. Biochem. 2015, 407, 89-95.
56. Hiratsuka, S.; Watanabe, A.; Sakurai, Y.; Akashi-Takamura, S.; Ishibashi, S.; Miyake, K.; Shibuya, M.; Akira, S.; Aburatani, H.; Maru, Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10, 1349-1355.
57. Deguchi, A.; Tomita, T.; Ohto, U.; Takemura, K.; Kitao, A.; Akashi-Takamura, S.; Miyake, K.; Maru, Y. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment. Oncogene 2016, 35, 1445-1456.
58. Chen, R.; Li, L.; Weng, Z. Zdock: An initial-stage protein-docking algorithm. Proteins 2003, 52, 80-87.
59. Gerke, V.; Creutz, C.E.; Moss, S.E. Annexins: Linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. 2005, 6, 449-461.
60. Zhang, S.; Yu, M.; Guo, Q.; Li, R.; Li, G.; Tan, S.; Li, X.; Wei, Y.; Wu, M. Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway. Sci. Rep. 2015, 5, 15859.
61. Bordoli, L.; Kiefer, F.; Arnold, K.; Benkert, P.; Battey, J.; Schwede, T. Protein structure homology modeling using swiss-model workspace. Nat. Protoc. 2009, 4, 1-13.
62. Awasthi, S.; Anbanandam, A.; Rodgers, K.K. Structure of a TLR4-interacting SPA4 peptide. RSC Adv. 2015, 5, 27431-27438.
63. Tovchigrechko, A.; Vakser, I.A. GRAMM-X public web server for protein-protein docking. Nucleic Acids Res. 2006, 34, W310-W314.
64. Dumortier, H. When carbon nanotubes encounter the immune system: Desirable and undesirable effects. Adv. Drug Deliv. Rev. 2013, 65, 2120-2126.
65. Dong, J.; Ma, Q. Advances in mechanisms and signaling pathways of carbon nanotube toxicity. Nanotoxicology 2015, 9, 658-676.
66. Turabekova, M.; Rasulev, B.; Theodore, M.; Jackman, J.; Leszczynska, D.; Leszczynski, J. Immunotoxicity of nanoparticles: A computational study suggests that CNTs and C60 fullerenes might be recognized as pathogens by Toll-like receptors. Nanoscale 2014, 6, 3488-3495.
67. Barata, T.; Teo, I.; Lalwani, S.; Simanek, E.; Zloh, M.; Shaunak, S. Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex. Biomaterials 2011, 32, 8702-8711.
68. Joce, C.; Stahl, J.A.; Shridhar, M.; Hutchinson, M.R.; Watkins, L.R.; Fedichev, P.O.; Yin, H. Application of a novel in silico high-throughput screen to identify selective inhibitors for protein-protein interactions. Bioorg. Med. Chem. Lett. 2010, 20, 5411-5413.
69. Enamine database. Available online: http://www.enamine.net (accessed on 26 July 2016).
70. Svajger, U.; Brus, B.; Turk, S.; Sova, M.; Hodnik, V.; Anderluh, G.; Gobec, S. Novel Toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening. Eur. J. Med. Chem. 2013, 70, 393-399.
71. Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. Zinc: A free tool to discover chemistry for biology. J. Chem. Inform. Model. 2012, 52, 1757-1768.
72. O'Neill, L.A.; Bowie, A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007, 7, 353-364.
73. Narayanan, K.B.; Park, H.H. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis Int. J. Program. Cell Death 2015, 20, 196-209.
74. Xu, Y.; Tao, X.; Shen, B.; Horng, T.; Medzhitov, R.; Manley, J.L.; Tong, L. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000, 408, 111-115.
75. Hasan, U.; Chaffois, C.; Gaillard, C.; Saulnier, V.; Merck, E.; Tancredi, S.; Guiet, C.; Brière, F.; Vlach, J.; Lebecque, S. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 2005, 174, 2942-2950.
76. Ohnishi, H.; Tochio, H.; Kato, Z.; Orii, K.E.; Li, A.; Kimura, T.; Hiroaki, H.; Kondo, N.; Shirakawa, M. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc. Natl. Acad. Sci. USA 2009, 106, 10260-10265.
77. Loiarro, M.; Sette, C.; Gallo, G.; Ciacci, A.; Fantò, N.; Mastroianni, D.; Carminati, P.; Ruggiero, V. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of nf-κb. J. Biol. Chem. 2005, 280, 15809-15814.
78. Jiang, Z.; Georgel, P.; Li, C.; Choe, J.; Crozat, K.; Rutschmann, S.; Du, X.; Bigby, T.; Mudd, S.; Sovath, S. Details of Toll-like receptor: Adapter interaction revealed by germ-line mutagenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 10961-10966.
79. Lin, Z.; Lu, J.; Zhou, W.; Shen, Y. Structural insights into TIR domain specificity of the bridging adaptor mal in TLR4 signaling. PLoS ONE 2012, 7, e34202.
80. Dunne, A.; Ejdebäck, M.; Ludidi, P.L.; O'Neill, L.A.; Gay, N.J. Structural complementarity of Toll/interleukin-1 receptor domains in toll-like receptors and the adaptors Mal and MyD88. J. Biol. Chem. 2003, 278, 41443-41451.
81. Kubarenko, A.; Frank, M.; Weber, A. Structure-function relationships of Toll-like receptor domains through homology modelling and molecular dynamics. Biochem. Soc. Trans. 2007, 35, 1515-1518.
82. Gong, J.; Wei, T.; Stark, R.W.; Jamitzky, F.; Heckl, W.M.; Anders, H.J.; Lech, M.; Rössle, S.C. Inhibition of toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: A computational approach. J. Struct. Biol. 2010, 169, 323-330.
83. Miguel, R.N.; Wong, J.; Westoll, J.F.; Brooks, H.J.; O1 Neill, L.A.; Gay, N.J.; Bryant, C.E.; Monie, T.P. A dimer of the Toll-like receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS ONE 2007, 2, e788.
84. Basith, S.; Manavalan, B.; Govindaraj, R.G.; Choi, S. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L. PLoS ONE 2011, 6, e23989.
85. Guven-Maiorov, E.; Keskin, O.; Gursoy, A.; VanWaes, C.; Chen, Z.; Tsai, C.-J.; Nussinov, R. The architecture of the TIR domain signalosome in the Toll-like receptor-4 signaling pathway. Sci. Rep. 2015, 5, 13128.
86. Bovijn, C.; Ulrichts, P.; de Smet, A.-S.; Catteeuw, D.; Beyaert, R.; Tavernier, J.; Peelman, F. Identification of interaction sites for dimerization and adapter recruitment in Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 4. J. Biol. Chem. 2012, 287, 4088-4098.
87. Singh, S.; Pandey, K.; Rathore, Y.S.; Sagar, A.; Pattnaik, U.B.K.; Ashish. A communication network within the cytoplasmic domain of Toll-like receptors has remained conserved during evolution. J. Biomol. Struct. Dyn. 2014, 32, 694-700.